LANTHEUS BIOSCIENCES LTD.
Get an alert when LANTHEUS BIOSCIENCES LTD. files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-09-30
Confirmation statement due
2026-07-11 (in 2mo)
Last made up 2025-06-27
Watchouts
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
6 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Accounts
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Director's assessments and sensitivity analysis show that the Company has sufficient cash at hand to continue to meet its obligations as they fall due and as a result it is appropriate to prepare these financial statements on a going concern basis.”
Group structure
- LANTHEUS BIOSCIENCES LTD. · parent
- Life Molecular Imaging GmbH 100%
Significant events
- “In January 2025, Life Medical Group Limited (LMGL), an indirect wholly owned subsidiary of Life Healthcare Group, entered into binding agreements for the sale of 100% of the issued share capital of Life Molecular Imaging Limited (LMI) to Lantheus Radiopharmaceuticals UK Limited, a subsidiary of Lantheus Holdings Inc.”
- “The transaction, valued at USD 350 million up front with potential earnout payments of up to USD 400 million linked to future sales milestones of LMI products until 2034, signifies a strategic partnership aimed at advancing radiopharmaceutical innovation. The sale is subject to certain conditions that must be met before completion.”
- “In October 2024, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Kisunla for treating early-stage Alzheimer's disease and also in October 2024 Japan's Ministry of Health, Labor and Welfare approved Eli Lilly's Kisunla (donanemab) for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and mild dementia.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 24 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MARSHALL, JR, Robert J | Director | 2025-07-21 | May 1966 | American |
| NIEDZWIECKI, Daniel | Director | 2025-07-21 | Dec 1976 | American |
Show 24 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BEUKMAN, Nico Francois | Secretary | 2014-06-03 | 2018-06-25 |
| CATTERMOLE, Ian Kendal | Secretary | 2018-06-25 | 2018-09-01 |
| HUMPHRIES, Roderick John | Secretary | 2003-07-08 | 2014-06-03 |
| BEUKMAN, Nico Francois | Director | 2014-05-21 | 2025-07-25 |
| CHAPMAN, Mark David | Director | 2021-06-16 | 2024-01-31 |
| DINKELBORG, Ludger Maria Theodor, Dr | Director | 2014-05-21 | 2025-07-25 |
| DSOUZA, Leonard Joseph Peter | Director | 2011-12-20 | 2012-04-16 |
| GAUSE, Friedrich-Wilhelm | Director | 2014-05-21 | 2015-12-31 |
| JONGENS, Michel Pieter | Director | 2019-06-01 | 2025-08-11 |
| KLEMENT, Gerhard Franz | Director | 2011-01-11 | 2012-01-31 |
| LADDHA, Rajesh | Director | 2012-04-16 | 2016-04-07 |
| LUNT, Edward Henry | Director | 2018-06-25 | 2019-04-26 |
| MARKISON, Brian | Director | 2025-07-21 | 2025-12-31 |
| MARSH, Howard Alexander David | Director | 2021-06-16 | 2024-01-31 |
| MARSH, Howard Alexander David | Director | 2018-06-25 | 2019-05-02 |
| NARAYANSWAMY, Santhanam | Director | 2011-01-11 | 2011-12-20 |
| SHAH, Prashant Shirish | Director | 2008-01-31 | 2011-01-11 |
| SHAH, Prashant Shirish | Director | 2003-07-08 | 2004-08-26 |
| SHAH, Sunil Rajen | Director | 2003-07-08 | 2014-02-17 |
| SHAH, Vijay | Director | 2012-01-31 | 2016-04-07 |
| UPADHYAY, Kaushik | Director | 2016-04-07 | 2018-06-25 |
| VALSARAJ, Vivek | Director | 2014-05-21 | 2018-06-25 |
| VAN DER WESTHUIZEN, Petrus Phillippus | Director | 2023-07-03 | 2025-07-21 |
| WHARTON HOOD, Peter Gerard | Director | 2023-07-03 | 2025-07-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Lantheus Radiopharmaceuticals Uk Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2025-07-21 | Active |
| Life Medical Group Limited | Corporate entity | Shares 75–100% | 2023-07-04 | Ceased 2025-07-21 |
| Alliance Medical Acquisition Co Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-06-25 | Ceased 2023-07-04 |
Filing timeline
Last 20 of 160 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-16 | CERTNM | change-of-name | Certificate change of name company | |
| 2026-01-22 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-29 | SH20 | capital | Legacy | |
| 2025-12-29 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-12-29 | CAP-SS | insolvency | Legacy | |
| 2025-12-29 | RESOLUTIONS | resolution | Resolution | |
| 2025-08-12 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-30 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-30 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-30 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-30 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-30 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-30 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-30 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-07-30 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-30 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2025-07-30 | AA01 | accounts | Change account reference date company current extended | |
| 2025-07-07 | AA | accounts | Accounts with accounts type full | |
| 2025-07-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-04-25 | RP04SH01 | capital | Second filing capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 19
- Capital events
- 3
- Officers appointed
- 2
- Officers resigned
- 6
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
Latest filed period vs the prior one